Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology
- Written by PR Newswire
- Teva-engineered TEV-56278 is an anti-PD1-IL2 ATTENUKINE™ therapy in Phase 1 for the treatment of various forms of cancer, including melanoma
- Fosun Pharma-Teva collaboration agreement established with goal of accelerating clinical data generation for TEV-56278
- Partnership leverages strategic relationships to enable research and development of...
